Key Points
- Insider sale: Johannes Jacob Piete Kastelein sold 125,000 NewAmsterdam Pharma shares at an average price of $26.91, totaling $3.36 million. His remaining ownership fell 64.33% to 69,302 shares.
- Financial performance: The company reported a quarterly loss of $0.52 per share, missing estimates by $0.04, while revenue of $3.70 million exceeded expectations.
- Market outlook: NAMS traded at $27.34, well below its 52-week high of $42.21. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $49.73, while institutional investors own 89.89% of the stock.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 125,000 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $26.91, for a total value of $3,363,750.00. Following the completion of the sale, the insider owned 69,302 shares in the company, valued at $1,864,916.82. This represents a 64.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NewAmsterdam Pharma Stock Up 1.8%
NAMS opened at $27.34 on Wednesday. The firm has a market cap of $3.27 billion, a P/E ratio of -12.66 and a beta of 0.10. The business's fifty day simple moving average is $30.53 and its 200 day simple moving average is $32.07. NewAmsterdam Pharma Company N.V. has a 52 week low of $23.05 and a 52 week high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. As a group, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in NewAmsterdam Pharma during the first quarter worth approximately $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company's stock valued at $5,898,000 after acquiring an additional 34,563 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company's stock valued at $1,800,000 after acquiring an additional 13,629 shares in the last quarter. Legal & General Group Plc boosted its position in NewAmsterdam Pharma by 33.5% during the 2nd quarter. Legal & General Group Plc now owns 44,235 shares of the company's stock worth $801,000 after purchasing an additional 11,106 shares during the period. Finally, Invesco Ltd. boosted its position in NewAmsterdam Pharma by 12.7% during the 2nd quarter. Invesco Ltd. now owns 134,035 shares of the company's stock worth $2,427,000 after purchasing an additional 15,101 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on NAMS. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They issued an "outperform" rating and a $58.00 price target for the company. Royal Bank Of Canada reduced their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $49.73.
Get Our Latest Stock Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
